Relationship between parathyroid hormone and left ventricular mass in moderate essential hypertension

Duprez, Daniel; Bauwens, Frank; Buyzere, Marc De; Backer, Tine De; Kaufman, Jean-Marc M.; Hoecke, Jose Van; Vermeulen, A.; Clément, Denis

doi:10.1097/00004872-199112000-00042

Cited by 6 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…20 Further evidence for the role of secondary hyperparathyroidism in the pathogenesis of CKD-related cardiovascular disease can be derived from clinical and experimental studies. Both primary and secondary hyperparathyroidism are associated with left ventricular hypertrophy, 21,22 and in the context of hemodialysis, parathyroidectomy improves left ventricular function. 23 Cardiovascular benefits of cinacalcet could also result from a reduction in calcification of the cardiovascular system.…”

Section: Discussionmentioning

confidence: 99%

Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial

Wheeler

London²,

Parfrey

et al. 2014

JAHA

113

View full text Add to dashboard Cite

BackgroundPremature cardiovascular disease limits the duration and quality of life on long‐term hemodialysis. The objective of this study was to define the frequency of fatal and nonfatal cardiovascular events attributable to atherosclerotic and nonatherosclerotic mechanisms, risk factors for these events, and the effects of cinacalcet, using adjudicated data collected during the EValuation of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial.Methods and ResultsEVOLVE was a randomized, double‐blind, placebo‐controlled clinical trial that randomized 3883 hemodialysis patients with moderate to severe secondary hyperparathyroidism to cinacalcet or matched placebo for up to 64 months. For this post hoc analysis, the outcome measure was fatal and nonfatal cardiovascular events reflecting atherosclerotic and nonatherosclerotic cardiovascular diseases. During the trial, 1518 patients experienced an adjudicated cardiovascular event, including 958 attributable to nonatherosclerotic disease. Of 1421 deaths during the trial, 768 (54%) were due to cardiovascular disease. Sudden death was the most frequent fatal cardiovascular event, accounting for 24.5% of overall mortality. Combining fatal and nonfatal cardiovascular events, randomization to cinacalcet reduced the rates of sudden death and heart failure. Patients randomized to cinacalcet experienced fewer nonatherosclerotic cardiovascular events (adjusted relative hazard 0.84, 95% CI 0.74 to 0.96), while the effect of cinacalcet on atherosclerotic events did not reach statistical significance.ConclusionsAccepting the limitations of post hoc analysis, any benefits of cinacalcet on cardiovascular disease in the context of hemodialysis may result from attenuation of nonatherosclerotic processes.Clinical Trials RegistrationUnique identifier: NCT00345839. URL: ClinicalTrials.gov.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial

Wheeler

London²,

Parfrey

et al. 2014

JAHA

113

View full text Add to dashboard Cite

show abstract

“…[20][21][22][23][24] Secondary hyperparathyroidism is also associated with left ventricular hypertrophy. [25][26][27][28][29] In combination with the higher prevalence of hypertension, this could contribute to the greater prevalence of congestive heart failure in SHPT patients. Several studies have suggested that hyperlipemia in renal failure is related to elevated PTH levels.…”

Section: Discussionmentioning

confidence: 99%

Survival after Parathyroidectomy in Patients with End‐stage Renal Disease and Severe Hyperparathyroidism

et al. 2007

View full text Add to dashboard Cite

show abstract

“…However, the etiopathogenic mechanisms underlying this association and the exact role of PHPT in the development of cardiovascular disease are not fully understood [21]. Some studies show a positive correlation between PTH levels and blood pressure in patients with normotensive, healthy subjects and hypertension [22,23].…”

Section: Discussionmentioning

confidence: 99%

Impairment of flow mediated vasodilatation of brachial artery in patients with primary hyperparathyroidism

Baykan¹,

Erem²,

Erdoğan³

et al. 2006

Int J Cardiovasc Imaging

View full text Add to dashboard Cite

show abstract

Relationship between parathyroid hormone and left ventricular mass in moderate essential hypertension

Cited by 6 publications

References 0 publications

Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial

Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial

Survival after Parathyroidectomy in Patients with End‐stage Renal Disease and Severe Hyperparathyroidism

Impairment of flow mediated vasodilatation of brachial artery in patients with primary hyperparathyroidism

Contact Info

Product

Resources

About